Crystal's Coder Hub🧬 ICD-10 CM Z85.51 — Personal History of Malignant Neoplasm of Bladder
Billable Code Confirmed
ICD-10 CM Z85.51 is a valid, billable FY2026 ICD-10-CM diagnosis code in Chapter 21 under personal history of malignant neoplasm. It is used when a bladder malignancy has been previously excised or eradicated, no further treatment is directed to that site, and there is no evidence of any existing primary malignancy at that site. The code is POA-exempt on inpatient claims and is explicitly designated as unacceptable as a principal diagnosis, meaning it will always be reported as a secondary or additional code.^1,2,3
Non-Billable Parent Codes
Z85.5 is a non-billable parent subcategory for personal history of malignant neoplasm of the urinary tract. It groups bladder and other urinary tract history codes together but does not specify the site within the urinary tract, making it insufficiently specific for claim submission.^1,2
Z85 is a non-billable category header for personal history of all malignant neoplasms. It carries the category-level instructional notes including the Excludes2 for benign neoplasm and carcinoma-in-situ history codes, the “code first” instruction for Z08 follow-up encounters, and the “use additional code” tobacco and alcohol use instructions. It should never appear as a final coded diagnosis.^1,2
Clinical Context
ICD-10 CM Z85.51 is appropriate only after three conditions are all simultaneously true: the bladder malignancy has been previously excised or eradicated from its site; there is no further treatment being directed to that site; and there is no evidence of existing primary malignancy at that site. Until all three conditions are met, the active malignancy code from category C67.- must be used rather than the personal history code. Surveillance cystoscopy or follow-up monitoring does not constitute active treatment and does not prevent use of Z85.51 when the three conditions above are met.^2,3,4,5
Code Classification
ICD-10 CM Z85.51 is a Chapter 21 Z code describing a patient’s personal health history circumstance. It is not an active disease code, not a procedure code, and not an ICD-10-PCS code. It is always a secondary or additional code and is explicitly unacceptable as a principal inpatient diagnosis per CMS designation.^1,2
🔍 Code Description
ICD-10 CM Z85.51 captures the clinical circumstance in which a patient has a documented prior bladder malignancy that has been fully treated and is no longer active, placing the patient in a post-treatment surveillance state rather than an active-cancer-treatment state. The ICD-10-CM Official Guidelines for Coding and Reporting state explicitly in Section I.C.2 that when a primary malignancy has been excised or eradicated, there is no further treatment directed to that site, and there is no evidence of existing primary malignancy, a code from category Z85 should be assigned. The switch from the active C67.- malignancy code to Z85.51 is one of the most consequential and frequently misapplied transitions in oncology and urology coding, because prematurely using the history code when treatment is still ongoing misrepresents the clinical encounter and may trigger denials for active-treatment services.^2,3,4
The category Z85 carries several important instructional notes that directly affect how Z85.51 is reported. The “code first” note directs that when the encounter is a follow-up examination after completed treatment for a malignant neoplasm, Z08 should be sequenced as the principal diagnosis before Z85.51. The “use additional code” notes at the category level require coders to also capture tobacco-related codes — including Z87.891 for history of tobacco dependence, F17.- for active tobacco dependence, Z72.0 for tobacco use, and alcohol use codes — when those factors are documented, because tobacco use is a major established risk factor for bladder cancer recurrence. CMS has also listed Z85.51 specifically in billing and coding coverage articles for bladder and urothelial tumor marker lab surveillance, confirming its role in supporting medical necessity for post-treatment monitoring services.^1,2,5,6
🌳 Code Tree / Hierarchy
Z85 Personal history of malignant neoplasm ❌ Non-billable
│
├── Z85.0 Personal history of malignant neoplasm of digestive organs ❌ Non-billable
├── Z85.1 Personal history of malignant neoplasm of trachea, bronchus, and lung ❌ Non-billable
├── Z85.2 Personal history of malignant neoplasm of other respiratory and intrathoracic organs ❌ Non-billable
├── Z85.3 Personal history of malignant neoplasm of breast ✅ Billable
├── Z85.4 Personal history of malignant neoplasm of genital organs ❌ Non-billable
│
├── Z85.5 Personal history of malignant neoplasm of urinary tract ❌ Non-billable
│ │
│ ├── Z85.50 Personal history of malignant neoplasm of unspecified urinary tract organ ✅ Billable
│ ├── Z85.51 Personal history of malignant neoplasm of bladder ◀ THIS CODE ✅ Billable
│ ├── Z85.52 Personal history of malignant neoplasm of kidney ✅ Billable
│ ├── Z85.53 Personal history of malignant neoplasm of renal pelvis ✅ Billable
│ ├── Z85.54 Personal history of malignant neoplasm of ureter ✅ Billable
│ └── Z85.59 Personal history of malignant neoplasm of other urinary tract organ ✅ Billable
│
├── Z85.6 Personal history of leukemia ✅ Billable
└── Z85.7 Personal history of other malignant neoplasms of lymphoid, hematopoietic, and related tissues ❌ Non-billable
The Three-Condition Rule for Using Z85.51
The ICD-10-CM guideline requires ALL THREE of these conditions to be documented before Z85.51 replaces the active C67.- code: (1) the malignancy has been excised or eradicated; (2) there is no further treatment directed to that site; and (3) there is no evidence of existing primary malignancy. Failing even one of these conditions means the active malignancy code stays. A patient still receiving BCG intravesical therapy fails condition 2, even if the tumor appears to be gone.^2,3,4
Tip
Surveillance cystoscopy is NOT active treatment. A patient on a routine 3-month cystoscopy surveillance schedule with no active disease and no ongoing antineoplastic treatment meets all three conditions for Z85.51. The surveillance itself is coded with Z08 as the principal diagnosis for those follow-up encounters, with Z85.51 following.^2,3,5
✅ Includes
- Bladder malignancy that has been completely surgically excised (e.g., transurethral resection of bladder tumor/TURBT or radical cystectomy) with no further antineoplastic treatment directed to the bladder site and no evidence of recurrence.^2,3,4
- Post-radiation therapy or post-chemotherapy state for bladder cancer when all planned treatment has been completed, no additional courses are scheduled, and no active disease is documented.^2,4
- Bladder cancer in long-term remission where the provider documents completion of treatment and absence of active disease, and the encounter is surveillance-based rather than treatment-based.^2,5
- History of urothelial carcinoma of the bladder after full treatment completion. Urothelial carcinoma is the most common histologic type of bladder cancer, and Z85.51 captures its personal history regardless of the original histologic subtype as long as the primary site was the bladder.^3,4
- Encounters for follow-up cystoscopy, urinary biomarker testing (Z08 as principal), or imaging surveillance where no active disease is found, and the encounter purpose is monitoring for recurrence after completed treatment.^2,5,6
❌ Excludes
Excludes 1
- No Excludes1 note was confirmed directly at the Z85.51 level per reviewed sources. The primary coding restriction at this code is the unacceptable-as-principal-diagnosis designation and the condition-based guidelines governing when Z85.51 replaces an active C67.- code.^1,2
Danger
The most significant and high-frequency error with Z85.51 is using it when active treatment is still ongoing. ICD-10-CM Section I.C.2 guidelines are explicit: as long as any treatment — including BCG intravesical instillation, systemic chemotherapy, immunotherapy, or radiation — is still directed to the bladder site, the active malignancy code from C67.- must be used, not Z85.51. Prematurely switching to the personal history code during active treatment misrepresents the encounter, may cause denial of antineoplastic treatment services, and can create audit liability.^2,3,4
Excludes 2
- Z86.00- — Personal history of carcinoma-in-situ (noted at the Z85 category level). Prior carcinoma-in-situ of the bladder, such as D09.0, is captured under the Z86.00- code family rather than Z85.51 when the prior lesion was in-situ rather than invasive malignant. Both codes may coexist on the same claim when a patient has history of both an in-situ lesion and a separate invasive malignancy.^1,2
- Z86.01- — Personal history of benign neoplasm (noted at the Z85 category level). Prior benign bladder neoplasms are captured under Z86.01- rather than under Z85.51, which is restricted to history of malignant neoplasm only.^1,2
📋 Clinical Overview
Active Bladder Cancer vs. Personal History — The Critical Transition
The single most important clinical coding decision with Z85.51 is determining when to transition from an active C67.- malignancy code to the personal history code. Getting this wrong in either direction creates compliance and reimbursement problems.^2,3,4
| Feature | Active Code C67.9 / C67.- | Z85.51 | Z08 |
|---|---|---|---|
| Condition status | Active malignancy currently present or under active treatment.^2,3 | Prior malignancy fully treated, no evidence of disease, no active treatment to site.^2,3,4 | Follow-up encounter after completed cancer treatment; used as principal diagnosis for surveillance visits.^2,5 |
| Treatment status | Any ongoing antineoplastic treatment — surgery, chemo, radiation, BCG, immunotherapy — is still directed to the bladder site.^2,3,4 | All treatment to the bladder site is complete; no further antineoplastic treatment planned or ongoing.^2,3,4 | No active treatment; encounter is specifically for monitoring, surveillance, or follow-up examination.^2,5 |
| Surveillance coding | Not used for surveillance; active cancer code covers the clinical picture while treatment is ongoing.^2,3 | Used as secondary code during surveillance encounters alongside Z08 as principal.^2,5 | Principal diagnosis for follow-up examination encounters; Z85.51 follows as the secondary history code.^2,5 |
Important
The CDI trigger most associated with Z85.51 errors is the bladder cancer patient still receiving BCG intravesical therapy. BCG is an antineoplastic treatment directed to the bladder site, meaning C67.- must remain as the active code until BCG is fully completed — even if no visible tumor is present on cystoscopy. The treating urologist’s documentation of whether BCG is ongoing or concluded is the determining factor, making this a prime CDI query scenario.^2,3,4
Manifestations & Surveillance Burden
- Routine surveillance cystoscopy is the most common clinical activity associated with Z85.51 documentation. These follow-up encounters are coded with Z08 as the principal diagnosis and Z85.51 as the secondary code when no recurrence is found.^2,5
- Urinary biomarker testing (such as UroVysion FISH or NMP22) may be ordered during surveillance and is supported by Z85.51 as a medical necessity anchor per CMS coverage articles for bladder and urothelial tumor markers.
- Hematuria assessment or unspecified urinary symptoms may arise in patients with Z85.51 and may require evaluation to rule out recurrence. When recurrence is confirmed, the active C67.- code must be reinstated immediately.^3,4
- Complications of prior treatment — such as radiation cystitis, post-cystectomy complications, or urinary diversion management — may represent the reason for an inpatient admission and should be coded with the appropriate complication code as principal, with Z85.51 as a relevant secondary code.^3,4
- Tobacco use documentation is clinically critical in bladder cancer patients because tobacco is a major risk factor for recurrence. The **Z85 category-level “use additional code” instruction requires tobacco-related codes to be reported when documented alongside Z85.51.^1,2
Tip
If recurrence is documented at any follow-up encounter, Z85.51 must be dropped immediately and replaced with the appropriate active C67.- or C79.- metastatic code. The personal history code cannot coexist with an active malignancy code for the same site. Once active treatment begins again, Z85.51 is gone from that claim until the new treatment course is fully completed and the three-condition rule is met again.^2,3,4
💰 HCC Risk Adjustment
| Item | Detail |
|---|---|
| HCC status | Not HCC-mapped per sources reviewed; Z85.51 carries no independent HCC RAF value.^7 |
| RAF impact | No additional risk adjustment value for the personal history Z code itself.^7 |
| Active cancer transition | If active malignancy is confirmed (recurrence), the active C67.- or metastatic code reinstated will carry any applicable HCC value.^7 |
| Surveillance role | Z85.51 supports medical necessity for surveillance services but does not generate HCC-based RAF.^6,7 |
| Annual documentation | Accurate annual documentation of treatment completion and no evidence of disease is essential to justify continued use of Z85.51 over an active malignancy code.^2,4 |
ICD-10 CM Z85.51 holds no HCC risk-adjustment value on its own, but its accurate use protects the integrity of the coded record by clearly documenting the boundary between active cancer and post-treatment surveillance status. Payers and auditors reviewing claims for bladder-cancer-related services will look for consistency between the diagnosis code reported and the type of service billed — active treatment codes paired with surveillance-only services raise flags, and personal history codes paired with antineoplastic treatment services are equally problematic. From a risk-adjustment audit perspective, the question is not whether Z85.51 generates RAF but whether its use is clinically justified and consistently applied across the record.^2,4,7
🏥 MS-DRG Assignment
| Element | Detail |
|---|---|
| Principal Dx designation | Unacceptable as principal diagnosis per CMS designation.^1,2 |
| POA status | POA-exempt — no POA indicator required on the inpatient UB-04.^1,2 |
| DRG assignment basis | Driven entirely by the principal diagnosis and full claim context; Z85.51 is always secondary.^8 |
| Inpatient role | Secondary code that provides clinical context for prior bladder cancer history relevant to the current admission.^2,4 |
| CC/MCC status | Z85.51 is not a CC or MCC; does not independently shift DRG weight.^8 |
In the inpatient profee setting, Z85.51 most commonly appears as a secondary code when a patient with treated bladder cancer is admitted for an unrelated condition or for a complication related to prior cancer treatment such as radiation cystitis or post-cystectomy complications. The “code first” instruction at the Z85 category level for follow-up examination encounters requires Z08 as the principal diagnosis for those visits, which is a critical sequencing rule that prevents Z85.51 from accidentally landing in the principal position during surveillance admissions. CMS has flagged Z85.51 as unacceptable as a principal diagnosis, so any coding scenario that produces this code as the reason for admission should trigger a coder review of whether a more appropriate principal diagnosis — the condition that led to the admission — should be sequenced first.^1,2,8
🔗 Related ICD-10-CM Codes
Active Bladder Malignancy Codes (Z85.51 Precursors)
- C67.9 — Malignant neoplasm of bladder, unspecified; the active malignancy code used until all three conditions for history coding are met.^2,3
- C67.0 — Malignant neoplasm of trigone of bladder; site-specific active code.
- D09.0 — Carcinoma in situ of bladder; active in-situ code before treatment; history maps to Z86.00- family, not Z85.51.^1,2
Personal History and Follow-Up Companion Codes
- Z08 — Encounter for follow-up examination after completed treatment for malignant neoplasm; mandatory principal diagnosis for surveillance follow-up encounters, with Z85.51 as the secondary code.^2,5
- Z85.52 — Personal history of malignant neoplasm of kidney; sibling code in the urinary tract personal history family.^1,2
- Z85.53 — Personal history of malignant neoplasm of renal pelvis; sibling code in the urinary tract personal history family.^1,2
- Z85.54 — Personal history of malignant neoplasm of ureter; sibling code in the urinary tract personal history family.^1,2
- Z87.891 — Personal history of nicotine dependence; required additional code per Z85 category instruction when documented.^1,2
- Z77.22 — Contact with and (suspected) exposure to environmental tobacco smoke; required additional code per Z85 category instruction when documented.^1,2
🛠️ Commonly Associated CPT Codes
- 52000 — Cystourethroscopy; the primary surveillance procedure for post-treatment bladder cancer monitoring, most frequently paired with Z08 and Z85.51 for cystoscopy surveillance encounters.^5,6
- 51720 — Bladder instillation of anticarcinogenic agent (including retention time); used during active BCG or mitomycin treatment — note that this CPT should be paired with active C67.- codes, NOT Z85.51, since treatment is still ongoing when this procedure is billed.
- 86316 — Immunoassay for tumor antigen, other antigen, quantitative (e.g., CA 19-9, CA 125); used for urinary biomarker surveillance testing supported by Z85.51 per CMS coverage articles.
- 88112 — Cytopathology, selective cellular enhancement technique with interpretation (e.g., liquid based slide preparation method), except cervical or vaginal; used for urine cytology surveillance in bladder cancer history patients.
- 99213 / 99214 — Office outpatient E/M services; used for post-treatment surveillance visits where cystoscopy is reviewed and documented, with Z08 as principal and Z85.51 as secondary.^5,6
NCCI Bundling Considerations
NCCI bundling specifics for the CPT codes most associated with Z85.51 and bladder cancer surveillance were not directly confirmed in the reviewed sources for this diagnostic context, and current NCCI edits and payer-specific coverage requirements should be verified before claim submission. The distinction between surveillance cystoscopy (52000) paired with Z85.51/Z08 versus therapeutic cystoscopy with bladder instillation (51720) paired with active C67.- codes is one of the most important payer-facing distinctions in urology coding. Billing instillation procedure codes with a personal history diagnosis code rather than an active cancer code is a common claim denial trigger and audit flag.^3,5,6
🔬 ICD-10-PCS Crosswalk
- 0TBB8ZZ — Excision of bladder, via natural or artificial opening endoscopic. Transurethral resection of bladder tumor (TURBT) in the inpatient setting would be captured in ICD-10-PCS using the Excision root operation for bladder via endoscopic approach; this PCS code would have been used during the active treatment phase before the transition to Z85.51.
- 0TTB0ZZ — Resection of bladder, open approach. Radical cystectomy in the inpatient setting would use the Resection root operation for complete removal; again, associated with the active treatment phase rather than the personal history phase.
- 0T1B079 — Bypass bladder to cutaneous, open approach, autologous tissue substitute. Urinary diversion procedures following radical cystectomy would generate ICD-10-PCS bypass codes; management of prior urinary diversion in subsequent admissions may coexist with Z85.51 as a secondary code.
💊 Coding Scenarios and Examples
Scenario 1
A patient who underwent TURBT and completed a full course of intravesical BCG therapy 18 months ago presents for a routine 3-month surveillance cystoscopy. No recurrence is found on cystoscopy or biopsy. The urologist documents “personal history of transitional cell carcinoma of the bladder, surveillance cystoscopy, no evidence of recurrence.” All three conditions for personal history coding are met: tumor excised, BCG completed, no active disease.
Correct coding list: Principal — Z08 Encounter for follow-up examination after completed treatment for malignant neoplasm; Secondary — Z85.51
Sequencing explanation: Z08 is the mandatory principal diagnosis per the “code first” instruction at category Z85 for follow-up examination encounters; Z85.51 is the secondary code identifying the historical malignancy site.^2,5
CDI note: If the urologist documents that BCG is still ongoing in any cycle, Z85.51 must not be used — the active C67.- code applies until the full BCG course is confirmed complete.^2,3,4
Scenario 2
A patient with a known history of bladder cancer is currently undergoing intravesical BCG instillation (cycle 3 of 6 scheduled). The patient presents for the instillation procedure. Since BCG is antineoplastic treatment directed to the bladder site, this is an active treatment encounter. Z85.51 is not appropriate here — the active malignancy code must be used.
Correct coding list: Principal — C67.9 or appropriate specific C67.- code; Secondary — Z51.11 Encounter for antineoplastic chemotherapy
Sequencing explanation: The active malignancy code from C67.- is correct because treatment is still directed to the bladder site. Z85.51 would be a coding error here and may cause claim denials for the antineoplastic instillation service.^2,3,4
CDI note: Confirm with the treating urologist the status of BCG therapy — how many cycles have been given and how many remain — so the correct code family can be assigned.^2,3
Scenario 3
A patient with a prior history of bladder cancer (TURBT completed, BCG completed 2 years ago, no evidence of recurrence) is admitted for an unrelated acute MI. The bladder cancer history is documented in the PMH and the medication list includes no antineoplastic agents. The attending documents the history of bladder cancer as a past condition not currently affecting management of the MI.
Correct coding list: Principal — appropriate acute MI code; Secondary — Z85.51 if clinically relevant and documented; Z87.891 if history of nicotine dependence is documented
Sequencing explanation: The MI drives the principal position; Z85.51 is reported as a secondary code when the bladder cancer history is documented as clinically relevant; tobacco history should be captured per the Z85 category “use additional code” instruction when documented.^1,2,4
CDI note: Whether Z85.51 is reported as a secondary code on an unrelated admission depends on whether the provider documents the history as relevant to current care. If it is listed only in the PMH and not addressed in the encounter, facility policy and coder judgment govern whether to capture it as a secondary code.^2,4
⚠️ Coding Pitfalls and Tips
- Do not use Z85.51 while ANY antineoplastic treatment is still being directed to the bladder site. BCG, mitomycin C, systemic chemotherapy, radiation, or any ongoing pharmacologic or procedural cancer treatment means the active C67.- code must remain. This is the highest-frequency error in bladder cancer coding and is a known audit trigger.^2,3,4
- Always sequence Z08 as principal for surveillance/follow-up encounters, not Z85.51. The “code first” instruction at category Z85 is a mandatory sequencing directive for post-treatment follow-up examinations. Z85.51 as a principal diagnosis is explicitly unacceptable per CMS, and surveillance claims incorrectly listing it as principal will fail claim edits.^1,2,5
- Drop Z85.51 immediately upon confirmed recurrence. When a surveillance cystoscopy identifies a new tumor or biopsy confirms recurrence, the personal history code must be replaced with the active C67.- code on that encounter and all subsequent encounters until treatment is completed again.^2,3,4
- Capture the required tobacco and alcohol “use additional codes” per the Z85 category instruction. Tobacco use is a major bladder cancer risk factor and the tabular instruction at Z85 explicitly directs coders to also report Z87.891, F17.-, Z72.0, Z77.22, Z57.31, or alcohol use codes when those factors are documented. These are not optional — they are instructional-note directed additional codes.^1,2
- Do not confuse Z85.51 with D09.0 history. Prior carcinoma-in-situ of the bladder is historically captured under the Z86.00- code family, not Z85.51. Z85.51 covers prior invasive malignant neoplasm of the bladder specifically. If the patient’s history is of in-situ disease only, the correct history code is in the Z86.00- family.^1,2
- Do not use Z85.51 as a substitute for a current neoplasm status code when the cancer is in remission but remission documentation is not the same as “no active treatment and no evidence of disease.” Remission language and treatment completion language are not identical. If the provider documents remission but is still monitoring with active therapeutic intent, query before defaulting to the personal history code.^2,4